A new direction in metabolic research
The science of metabolic disease has changed rapidly over the past decade. One of the most important developments has been the growing ability to target several hormone receptors with a single molecule. Instead of studying only one signalling pathway at a time, researchers are now investigating whether coordinated activity at multiple receptors can produce broader metabolic effects.
This has brought increasing attention to so-called dual and triple agonists. Retatrutide is one of the best-known investigational examples. It is designed to activate three receptors involved in nutrient and energy regulation: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors.
Why GLP-1 became such an important research target
GLP-1 is a hormone released in response to food intake. Among its physiological roles are glucose-dependent stimulation of insulin secretion, suppression of glucagon under appropriate metabolic conditions, delayed gastric emptying and signalling involved in appetite and satiety. These characteristics made the GLP-1 receptor an important target in research into type 2 diabetes and obesity.
The success of GLP-1 receptor agonism also raised a broader question: could additional metabolic pathways be targeted at the same time? That question helped drive research into molecules that combine GLP-1 activity with other hormone-receptor mechanisms.
Adding GIP: the dual-agonist concept
GIP is another nutrient-stimulated incretin hormone. Like GLP-1, it participates in the regulation of insulin secretion after food intake, although its biology is distinct and more complex. Combining GIP and GLP-1 receptor agonism therefore became an important area of metabolic research.
The dual-agonist approach demonstrated that multi-receptor molecules could have clinically meaningful metabolic effects. From a research perspective, this created a logical next question: what might happen if a third pathway were incorporated?
Why researchers are interested in glucagon
Glucagon is often discussed primarily in relation to its ability to raise blood glucose, but its physiology extends beyond glucose regulation. Glucagon signalling is also involved in hepatic metabolism, substrate utilisation and energy expenditure. For this reason, carefully balanced glucagon-receptor activity has become an area of interest in next-generation metabolic drug development.
The challenge is balance. A triple agonist is not simply three independent drugs placed together. Its receptor activity and pharmacology have to be engineered so that the combined signalling produces a useful overall metabolic profile.
Retatrutide as a triple-receptor agonist
Retatrutide (LY3437943) is an investigational single peptide with agonist activity at the GIP, GLP-1 and glucagon receptors. For readers who want a broader background on the molecule and its mechanism, this retatrutide explained overview provides additional context.
A randomized Phase 2 trial published in The New England Journal of Medicine in 2023 enrolled 338 adults with obesity or overweight plus a weight-related condition. At 48 weeks, the reported mean body-weight change reached 24.2% in the 12 mg group, compared with 2.1% in the placebo group. The most common adverse events were gastrointestinal and were generally dose-related. The study also reported dose-dependent increases in heart rate that peaked at week 24 and subsequently declined.
Source: Jastreboff AM et al., New England Journal of Medicine, 2023 — Phase 2 trial of retatrutide for obesity
What has changed since the Phase 2 study?
The research programme has progressed substantially since the original Phase 2 publication. In 2026, Eli Lilly announced positive topline results from several Phase 3 studies in its TRIUMPH programme. In July 2026, the company reported that TRIUMPH-2 and TRIUMPH-3 met their primary endpoints in populations that included adults with obesity or overweight and type 2 diabetes, and adults with severe obesity and established cardiovascular disease.
In TRIUMPH-2, Lilly reported average weight reductions of up to 20.8% at 80 weeks. In TRIUMPH-3, the company reported average weight reductions of up to 22.6% at 80 weeks. These are company-announced topline results; detailed results from those two trials had not yet been published in peer-reviewed journals at the time of writing.
Source: Eli Lilly and Company, July 23, 2026 — TRIUMPH-2 and TRIUMPH-3 Phase 3 topline results
How single, dual and triple agonism differ
The distinction between these approaches is easiest to understand by looking at the number of receptor pathways intentionally targeted. Semaglutide is a GLP-1 receptor agonist. Tirzepatide combines GIP and GLP-1 receptor agonism. Retatrutide adds glucagon-receptor agonism to GIP and GLP-1 activity.
That does not mean that a higher number of receptor targets automatically makes one molecule ‘better’ than another. Different compounds have different evidence bases, indications, safety profiles and regulatory statuses. A more detailed comparison of retatrutide, tirzepatide and semaglutide can help explain the mechanistic differences without treating receptor count as a simple ranking system.
Why the triple-agonist concept matters scientifically
The importance of triple agonism goes beyond one investigational medicine. It reflects a wider change in metabolic research: researchers are increasingly exploring whether several complementary biological signals can be integrated into one molecule.
GLP-1 signalling can influence appetite, satiety and glucose-dependent insulin secretion. GIP adds a second incretin pathway. Glucagon signalling introduces another metabolic mechanism involving hepatic metabolism and energy balance. Studying these pathways together may improve understanding of how nutrient signalling, appetite regulation and energy expenditure interact.
It also creates new scientific questions. Researchers need to understand how receptor activity should be balanced, whether effects persist over longer periods, which populations benefit most, and how adverse events compare with established therapies. Large Phase 3 programmes are important because early efficacy findings alone cannot answer those questions.
Research results should not be confused with regulatory approval
An important distinction is that promising clinical-trial results do not equal regulatory approval. As of August 2026, retatrutide remains investigational and has not been approved by regulatory agencies. Eli Lilly states that it plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first quarter of 2027.
Source: Eli Lilly — What to know about retatrutide
This distinction is especially important in a fast-moving field. Online discussion can move faster than peer-reviewed publication and regulatory review. Readers should therefore distinguish between published clinical evidence, company-reported topline results, ongoing trials and approved medical treatments.
What researchers will be watching next
Several questions will shape the next stage of triple-agonist research. Longer-term safety and tolerability remain essential. Researchers will also examine how results vary across people with obesity, type 2 diabetes, cardiovascular disease and other obesity-related complications.
Another important question is whether the theoretical contribution of glucagon-receptor agonism translates into durable clinical advantages when combined with GIP and GLP-1 signalling. Phase 3 data provide a much larger evidence base than early-stage studies, but full peer-reviewed publications and regulatory review remain important steps.
Conclusion
Triple agonists represent an important development in metabolic research because they attempt to coordinate several biological pathways within a single molecule. Retatrutide has attracted particular scientific attention because it combines GIP, GLP-1 and glucagon receptor agonism and has progressed through a large Phase 3 programme.
The field is moving quickly, but careful interpretation remains essential. Strong trial results should be considered alongside safety data, peer-reviewed publication and regulatory evaluation. Regardless of the eventual regulatory outcome for individual compounds, the triple-agonist concept is likely to remain an important area for understanding how multiple hormone pathways can be combined in future metabolic research.
Author Bio
GetVital Peptides is a Netherlands-based platform focused on educational content about peptides and emerging areas of peptide research. More research-focused information and educational resources are available at GetVital Peptides.
References
• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389:514-526. DOI: 10.1056/NEJMoa2301972. Source
• Eli Lilly and Company. Retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3). July 23, 2026. Source
• Eli Lilly and Company. What to know about retatrutide. Accessed August 2026. Source
247healthblog.com comprises doctors, bloggers, medical marketers, volunteers and agencies who work together to help people live and stay healthy. We achieve these through writing and posting unique health tips.
